ATE311476T1 - Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) - Google Patents
Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)Info
- Publication number
- ATE311476T1 ATE311476T1 AT01306983T AT01306983T ATE311476T1 AT E311476 T1 ATE311476 T1 AT E311476T1 AT 01306983 T AT01306983 T AT 01306983T AT 01306983 T AT01306983 T AT 01306983T AT E311476 T1 ATE311476 T1 AT E311476T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- polymorphisms
- oatp
- organic anion
- oatpc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22690900P | 2000-08-23 | 2000-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311476T1 true ATE311476T1 (de) | 2005-12-15 |
Family
ID=22850936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01306983T ATE311476T1 (de) | 2000-08-23 | 2001-08-17 | Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c) |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20020090622A1 (de) |
| EP (2) | EP1186672B1 (de) |
| JP (1) | JP2002330758A (de) |
| AT (1) | ATE311476T1 (de) |
| CY (1) | CY1106070T1 (de) |
| DE (1) | DE60115349T2 (de) |
| DK (1) | DK1186672T3 (de) |
| ES (1) | ES2252159T3 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE431361T1 (de) * | 1999-09-21 | 2009-05-15 | Chugai Pharmaceutical Co Ltd | Verwendung vom transportergen oatp-c zur screening von testsubstanzen |
| GB0213580D0 (en) * | 2002-06-13 | 2002-07-24 | Astrazeneca Ab | Methods |
| GB0317592D0 (en) * | 2003-07-26 | 2003-08-27 | Astrazeneca Ab | Method |
| WO2006008656A2 (en) * | 2004-07-21 | 2006-01-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| FR2877013A1 (fr) | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
| US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
| ES2744797T3 (es) | 2008-02-29 | 2020-02-26 | Univ Oxford Innovation Ltd | Procedimiento de determinación de una dosis adecuada de estatina |
| US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
| US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
| EP2267153A1 (de) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identifizierung der Netrin-1-Rezeptor-unc5c-Genmutation bei festen Krebsen |
| WO2013056087A2 (en) | 2011-10-13 | 2013-04-18 | Boston Heart Diagnostics | Compositions and methods for treating and preventing coronary heart disease |
| WO2014068072A1 (en) | 2012-10-31 | 2014-05-08 | Institut Gustave-Roussy | Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors |
| US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
| WO2016081471A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
| JP7067896B2 (ja) * | 2017-10-27 | 2022-05-16 | シスメックス株式会社 | 品質評価方法、品質評価装置、プログラム、および記録媒体 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010006644A1 (en) * | 1997-07-31 | 2001-07-05 | David J. Bova | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| EP1141282A2 (de) * | 1998-08-07 | 2001-10-10 | Axys Pharmaceuticals, Inc. | Humäne anionstransporter-genen atnov |
-
2001
- 2001-08-10 US US09/925,731 patent/US20020090622A1/en not_active Abandoned
- 2001-08-17 EP EP01306983A patent/EP1186672B1/de not_active Expired - Lifetime
- 2001-08-17 DE DE60115349T patent/DE60115349T2/de not_active Expired - Lifetime
- 2001-08-17 EP EP05011183A patent/EP1589115A3/de not_active Withdrawn
- 2001-08-17 ES ES01306983T patent/ES2252159T3/es not_active Expired - Lifetime
- 2001-08-17 AT AT01306983T patent/ATE311476T1/de active
- 2001-08-17 DK DK01306983T patent/DK1186672T3/da active
- 2001-08-22 JP JP2001251461A patent/JP2002330758A/ja active Pending
-
2003
- 2003-10-31 US US10/698,808 patent/US20040235006A1/en not_active Abandoned
-
2006
- 2006-02-28 CY CY20061100280T patent/CY1106070T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1186672B1 (de) | 2005-11-30 |
| US20020090622A1 (en) | 2002-07-11 |
| EP1186672A2 (de) | 2002-03-13 |
| ES2252159T3 (es) | 2006-05-16 |
| EP1589115A3 (de) | 2006-05-31 |
| DE60115349T2 (de) | 2006-08-10 |
| CY1106070T1 (el) | 2011-06-08 |
| EP1589115A2 (de) | 2005-10-26 |
| DK1186672T3 (da) | 2006-03-06 |
| US20040235006A1 (en) | 2004-11-25 |
| DE60115349D1 (de) | 2006-01-05 |
| JP2002330758A (ja) | 2002-11-19 |
| EP1186672A3 (de) | 2002-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106070T1 (el) | Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene) | |
| IL225203A (en) | An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity | |
| IL153052A0 (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| NO20063624L (no) | FC region varianter | |
| DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
| NO20053855D0 (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
| DK1560812T3 (da) | Aminocyclohexyletherforbindelser og anvendelser deraf | |
| NO20064894L (no) | Beta-karboliner anvendbare for behandling av inflammatoriske sykdommer | |
| DE60235005D1 (de) | Nachweis der instabilität von mikrosatelliten und | |
| ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
| DE60313004D1 (de) | Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| PE20021098A1 (es) | ANTICUERPOS ESPECIFICOS DE CD44v6 | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
| EP1469084A3 (de) | Polymorphismen im menschlichen KDR Gene | |
| ATE495193T1 (de) | Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist | |
| BR0113099A (pt) | Gene e proteìna relacionados com esquizofrenia | |
| ATE494307T1 (de) | Neoplasma-spezifische antikörper und deren verwendungen | |
| EP2096120A3 (de) | Verwendung sekretierter Proteinprodukte zur Prävention und Behandlung von Erkrankungen der Bauchspeicheldrüse und/oder Adipositas und/oder des metabolischen Syndroms | |
| EP1130122A3 (de) | Methode zur Detektion von Polymorphismen des humanen EP1-R Gens | |
| WO2002072632A3 (en) | Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof. | |
| ATE528392T1 (de) | Neues protein und dessen dns | |
| ATE374260T1 (de) | Asthma-assoziiertes gen | |
| EP1184465A3 (de) | Verfahren zur Diagnose von Polymorphismen des humanen MCT-1 Gens sowie hierdurch definierte Wirkstoffe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1186672 Country of ref document: EP |